Published in Can J Psychiatry on February 01, 2014
Influence of Serotonin Transporter Gene Polymorphisms and Adverse Life Events on Depressive Symptoms in the Elderly: A Population-Based Study. PLoS One (2015) 1.38
Pharmacogenetics of antipsychotics. Can J Psychiatry (2014) 1.02
Prediction of long-term treatment response to selective serotonin reuptake inhibitors (SSRIs) using scalp and source loudness dependence of auditory evoked potentials (LDAEP) analysis in patients with major depressive disorder. Int J Mol Sci (2015) 0.77
Pursuit of the "truth" about mental illness: the significance of findings in neuropsychiatric research, and lessons from the past. Dialogues Clin Neurosci (2014) 0.75
TPH-2 Polymorphisms Interact with Early Life Stress to Influence Response to Treatment with Antidepressant Drugs. Int J Neuropsychopharmacol (2016) 0.75
Is there a role for antidepressant and antipsychotic pharmacogenetics in clinical practice in 2014? Can J Psychiatry (2014) 0.75
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95
The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry (2003) 21.70
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Allelic variation of human serotonin transporter gene expression. J Neurochem (1996) 7.08
A framework for interpreting genome-wide association studies of psychiatric disorders. Mol Psychiatry (2008) 5.80
The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology (2000) 5.14
Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90
Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron (2005) 4.78
No gene is an island: the flip-flop phenomenon. Am J Hum Genet (2007) 4.69
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A (1989) 4.66
Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet (2004) 3.91
A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet (1998) 3.59
Treatment of mood disorders. Nat Neurosci (2002) 3.13
Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet (1997) 3.12
Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry (1998) 3.07
The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology (2009) 3.01
Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry (2007) 2.87
A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry (2010) 2.77
Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science (2004) 2.64
Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet (2006) 2.55
Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry (2010) 2.41
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry (2006) 2.29
High dimensional endophenotype ranking in the search for major depression risk genes. Biol Psychiatry (2011) 2.23
A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol (2008) 2.23
Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol (1999) 2.21
Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial. Br J Psychiatry (2011) 2.18
A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry (2009) 2.15
Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med (2007) 2.02
MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn (2009) 1.89
Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry (2007) 1.88
The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol Psychiatry (2008) 1.86
Genetics of psychosis; insights from views across the genome. Hum Genet (2009) 1.68
Chaperoning of glucocorticoid receptors. Handb Exp Pharmacol (2006) 1.62
Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron (2008) 1.57
Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2009) 1.56
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry (2004) 1.54
Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol (2004) 1.53
Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry (2007) 1.53
5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist (2004) 1.52
Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry (2006) 1.49
Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.48
A splice variant of the G protein beta 3-subunit implicated in disease states does not modulate ion channels. Physiol Genomics (2003) 1.46
Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry (2009) 1.46
Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology (2000) 1.45
Serotonin transporter gene polymorphism and antidepressant response. Neuroreport (2000) 1.42
Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response. Am J Med Genet B Neuropsychiatr Genet (2003) 1.41
Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry (2004) 1.36
Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry (2002) 1.36
Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J (2009) 1.35
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol (2011) 1.33
Statistical methods for pathway analysis of genome-wide data for association with complex genetic traits. Adv Genet (2010) 1.33
Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics (2005) 1.32
SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet (2009) 1.32
Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets (2006) 1.29
The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol (2004) 1.29
Pharmacogenetics of antidepressant response. J Psychiatry Neurosci (2011) 1.28
Tryptophan hydroxylase 2 (TPH2) haplotypes predict levels of TPH2 mRNA expression in human pons. Mol Psychiatry (2006) 1.27
Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry (2005) 1.27
Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies. Brain Res (2006) 1.27
Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry (2004) 1.26
Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA (2006) 1.25
Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry (2009) 1.25
Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry (1998) 1.23
Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology (2005) 1.22
Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One (2008) 1.21
A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. J Psychiatr Res (2000) 1.19
Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res (2006) 1.18
Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol (2000) 1.17
Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett (2006) 1.16
Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. Arch Gen Psychiatry (2009) 1.15
Dopamine, depression and antidepressants. Fundam Clin Pharmacol (2004) 1.15
Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry (2004) 1.14
ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.14
Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry (2002) 1.13
Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology (2007) 1.13
Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics (2008) 1.12
Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord (2007) 1.11
The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) (2003) 1.09
Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry (2009) 1.08
The association of serotonin transporter genotypes and selective serotonin reuptake inhibitor (SSRI)-associated sexual side effects: possible relationship to oral contraceptives. Hum Psychopharmacol (2009) 1.08
Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry (2010) 1.07
Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J (2007) 1.07
Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit (2004) 1.07
The AmpliChip CYP450 genotyping test: Integrating a new clinical tool. Mol Diagn Ther (2006) 1.07
Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics (2009) 1.06
Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport (2000) 1.06
Interaction between genetic polymorphisms and stressful life events in first episode depression. J Affect Disord (2009) 1.06
The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. Pharmacogenomics J (2006) 1.04
A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry (1998) 1.04
DNA sequence variants of the FKBP5 gene are associated with unipolar depression. Int J Neuropsychopharmacol (2010) 1.04
5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol (2003) 1.03
Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol (2009) 1.02
Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res (1983) 1.02
Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J (2006) 1.02
Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology (2006) 1.01
Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett (2001) 1.01
Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry (2003) 1.01
ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics (2011) 1.00
Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry (2010) 1.00
Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology (2006) 1.00
Mindfulness based cognitive therapy for psychiatric disorders: a systematic review and meta-analysis. Psychiatry Res (2010) 3.46
Mindfulness-based stress reduction for stress management in healthy people: a review and meta-analysis. J Altern Complement Med (2009) 2.89
Does mindfulness training improve cognitive abilities? A systematic review of neuropsychological findings. Clin Psychol Rev (2010) 2.17
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry (2013) 1.97
The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2012) 1.70
Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry (2007) 1.60
Mindfulness-based interventions for chronic pain: a systematic review of the evidence. J Altern Complement Med (2011) 1.54
Influence of CLOCK gene polymorphism on circadian mood fluctuation and illness recurrence in bipolar depression. Am J Med Genet B Neuropsychiatr Genet (2003) 1.50
The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder. Eur Arch Psychiatry Clin Neurosci (2012) 1.49
Antidepressant effects of light therapy combined with sleep deprivation are influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Biol Psychiatry (2003) 1.48
HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. J Clin Psychopharmacol (2015) 1.42
Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. J Clin Psychopharmacol (2005) 1.41
Seasonal variations of lithium plasma levels. Psychiatry Res (2002) 1.38
Are mindfulness-based interventions effective for substance use disorders? A systematic review of the evidence. Subst Use Misuse (2013) 1.37
Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. Am J Med Genet B Neuropsychiatr Genet (2007) 1.35
Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol (2011) 1.33
Pharmacogenetics of antidepressant response. J Psychiatry Neurosci (2011) 1.28
Personality and attempted suicide. Analysis of anger, aggression and impulsivity. J Psychiatr Res (2009) 1.26
Mindfulness: top-down or bottom-up emotion regulation strategy? Clin Psychol Rev (2012) 1.14
ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.14
A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci Lett (2004) 1.11
Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. Int J Neuropsychopharmacol (2006) 1.10
Gene environment interaction studies in depression and suicidal behavior: An update. Neurosci Biobehav Rev (2013) 1.07
Possible association between -G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet (2003) 1.07
The 5-HTTLPR polymorphism and eating disorders: a meta-analysis. Int J Eat Disord (2011) 1.05
Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett (2004) 1.04
Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry (2013) 1.03
Depressive symptomatology is influenced by chronotypes. J Affect Disord (2009) 1.02
A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett (2004) 1.02
Serotonergic genes and suicide: a systematic review. Eur Neuropsychopharmacol (2013) 1.01
Focus on HTR2C: A possible suggestion for genetic studies of complex disorders. Am J Med Genet B Neuropsychiatr Genet (2009) 0.99
Cognitive status, depressive symptoms, and health status as predictors of functional disability among elderly persons with low-to-moderate education: The Faenza Community Aging Study. Am J Geriatr Psychiatry (2005) 0.99
BanI polymorphism of the cytosolic phospholipase A2 gene and mood disorders in the Korean population. Neuropsychobiology (2004) 0.98
Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol (2011) 0.98
Retrospective analysis of psychomotor agitation, hypomanic symptoms, and suicidal ideation in unipolar depression. Depress Anxiety (2006) 0.98
Psychological mechanisms of mindfulness-based interventions: what do we know? Holist Nurs Pract (2014) 0.98
The 5-HTTLPR polymorphism and posttraumatic stress disorder: a meta-analysis. J Trauma Stress (2013) 0.98
Mindfulness-based cognitive therapy versus psycho-education for patients with major depression who did not achieve remission following antidepressant treatment: a preliminary analysis. J Altern Complement Med (2012) 0.98
Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways. Int J Alzheimers Dis (2011) 0.97
Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clin Neuropharmacol (2011) 0.97
Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol (2011) 0.96
Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder. Am J Med Genet B Neuropsychiatr Genet (2009) 0.96
Influence of BDNF variants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia. Neuropsychobiology (2011) 0.93
How do genes exert their role? Period 3 gene variants and possible influences on mood disorder phenotypes. Eur Neuropsychopharmacol (2007) 0.93
Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Res (2012) 0.93
Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. J Psychiatr Res (2010) 0.93
Serotonin transporter 5HTTLPR polymorphism and affective disorders: no evidence of association in a large European multicenter study. Eur J Hum Genet (2004) 0.93
Occurrence of cognitive impairment and dementia after the age of 60: a population-based study from Northern Italy. Dement Geriatr Cogn Disord (2004) 0.92
Polymorphisms of heat shock protein 70 gene (HSPA1A, HSPA1B and HSPA1L) and schizophrenia. Neurosci Res (2005) 0.92
Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol (2013) 0.92
Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up. J Affect Disord (2008) 0.91
Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder. Eur Arch Psychiatry Clin Neurosci (2011) 0.91
Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs (2008) 0.89
Pharmacogenetics of antidepressant response: an update. Hum Genomics (2009) 0.89
The role of COMT gene variants in depression: Bridging neuropsychological, behavioral and clinical phenotypes. Neurosci Biobehav Rev (2013) 0.89
Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet (2013) 0.89
Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis. Psychiatry Clin Neurosci (2006) 0.88
Psychometric characteristic of the Italian version of the Temperament and Character Inventory--revised, personality, psychopathology, and attachment styles. Compr Psychiatry (2008) 0.88
Paroxetine for the treatment of depression: a critical update. Expert Opin Pharmacother (2012) 0.88
Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes. Prog Neuropsychopharmacol Biol Psychiatry (2008) 0.87
Effect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects. Eur Neuropsychopharmacol (2009) 0.87
Quetiapine XR: current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.87
Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics. Eur Arch Psychiatry Clin Neurosci (2011) 0.87
Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. Eur Neuropsychopharmacol (2009) 0.86
Glutathione S-transferase M1 polymorphism may contribute to schizophrenia in the Korean population. Psychiatr Genet (2004) 0.86
5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Int J Neuropsychopharmacol (2007) 0.86
Correlation of a set of gene variants, life events and personality features on adult ADHD severity. J Psychiatr Res (2009) 0.86
Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. Biomed Pharmacother (2008) 0.86
Clinical, psychological and environmental predictors of prospective suicide events in patients with Bipolar Disorder. J Psychiatr Res (2013) 0.86
Potential role of membrane-bound COMT gene polymorphisms in female depression vulnerability. J Affect Disord (2013) 0.86
European Group for the Study of Resistant Depression (GSRD)--where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol (2012) 0.86
Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.86
Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World J Biol Psychiatry (2011) 0.85
Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res (2009) 0.85
Serotonin transporter gene-linked polymorphic region: possible pharmacogenetic implications of rare variants. Psychiatr Genet (2006) 0.85
Effect of 5-haplotype of dysbindin gene (DTNBP1) polymorphisms for the susceptibility to bipolar I disorder. Am J Med Genet B Neuropsychiatr Genet (2007) 0.85
Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment. Pharmacogenet Genomics (2014) 0.84
Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. Curr Psychiatry Rep (2015) 0.84
Interaction between SERTPR and stressful life events on response to antidepressant treatment. Eur Neuropsychopharmacol (2008) 0.84
Monocyte chemoattractant protein-1 (MCP1) promoter -2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. Psychiatry Res (2004) 0.83
Interleukin-10 gene promoter polymorphism is not associated with schizophrenia in the Korean population. Psychiatry Clin Neurosci (2003) 0.83
MAOA and MAOB polymorphisms and anger-related traits in suicidal participants and controls. Eur Arch Psychiatry Clin Neurosci (2012) 0.83
AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. Eur Neuropsychopharmacol (2012) 0.83
Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a Community Mental Health Centre. BMC Psychiatry (2006) 0.83
Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsychopharmacol (2002) 0.83
Temperament and character of suicide attempters. J Psychiatr Res (2007) 0.83
Association analysis of heat shock protein 70 gene polymorphisms in schizophrenia. Eur Arch Psychiatry Clin Neurosci (2008) 0.83
Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. Expert Opin Pharmacother (2009) 0.83
HTR1B as a risk profile maker in psychiatric disorders: a review through motivation and memory. Eur J Clin Pharmacol (2009) 0.83
Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol (2004) 0.83
Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord (2005) 0.83
Serious suicidal behaviors: socio-demographic and clinical features in a multinational, multicenter sample. Nord J Psychiatry (2013) 0.83
Association study between glutathione S-transferase P1 polymorphism and schizophrenia in the Korean population. Prog Neuropsychopharmacol Biol Psychiatry (2003) 0.83